We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Letters |

Brain Imaging to Assess the Effects of Dopamine Agonists on Progression of Parkinson Disease

Roger L. Albin, MD; Thomas E. Nichols, PhD; Kirk A. Frey, MD, PhD
JAMA. 2002;288(3):311-313. doi:10.1001/jama.288.3.311.
Text Size: A A A
Published online


To the Editor: Based on the results of SPECT imaging, Dr Marek and colleagues1 discussed a possible "neuroprotective" effect of dopamine receptor agonists. Inspection of Figure 3 and the data in Table 2, however, suggest that the rates of decline of DAT binding in levodopa and pramipexole groups from 22 to 46 months have identical slopes. We found that 2-way analysis of variance, using the data from Table 2, demonstrated significant differences between the levodopa and pramipexole treatment groups but no interactions between time and treatment, confirming lack of difference in the rates of decline of DAT binding between the 2 groups. This is consistent with the identical clinical ratings of both groups at 46 months and argues against differential disease-modifying effect of the treatment arms. A true neuroprotective effect should produce diverging rates of decline with the effective treatment exhibiting slower rate of progression.2 In the study of Marek et al,1 only the slopes of DAT binding between initial scans (unmedicated baseline) and the second scan (first onmedication scan) are significantly different. This could be attributable to differential effects of levodopa and pramipexole on DAT binding.


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.